SIGN IN YOUR ACCOUNT TO HAVE ACCESS TO DIFFERENT FEATURES

FORGOT YOUR PASSWORD?

FORGOT YOUR DETAILS?

AAH, WAIT, I REMEMBER NOW!

MITUMITU

info@mitu.or.tz | +255 28 2500019 | Staff Mail
  • LOGIN
  • WHO WE ARE
    • History & Background
    • Mission & Values
    • Strategic Plan
    • Organization Structure
    • Our Team
  • WHERE WE ARE
    • Mwanza Medical Research Centre
    • Mwanza City
  • WHAT WE DO
    • Research Programme
    • Capacity Building
    • Research Facilities
  • PUBLICATIONS
  • NEWS & EVENTS
    • News & Events
    • Career
  • CONTACT US
Thursday, 29 March 2012 / Published in 2007, Publication

Risk factors for Herpes simplex virus type 2 and HIV among women at high risk in north-western Tanzania: preparing for an HSV-2 intervention trial. Journal of Acquired Immune Deficiency Syndromes 2007; 46: 631-642.

Risk factors for Herpes simplex virus type 2 and HIV among women at high risk in north-western Tanzania: preparing for an HSV-2 intervention trial. Journal of Acquired Immune Deficiency Syndromes 2007; 46: 631-642.

Watson-Jones D, Weiss HA, Rusizoka M, Baisley K, Mugeye K, Changalucha J, Everett D, Balira R, Knight L, Ross D, Hayes RJ.
Journal of Acquired Immune Deficiency Syndromes 2007; 46: 631-642.
PMID: 18043318
Related citation

What you can read next

The epidemiology of HIV and HSV-2 infections among women participating in microbicide and vaccine feasibility studies in northern Tanzania.
Learning from people with HIV: Their insights are critical to our response to the intersecting COVID-19 and HIV pandemics in Africa.
Human papillomavirus (HPV) vaccine implementation in low and middle-income countries

Filter by Year

  • All Publications
  • 2025
  • 2024
  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • 2013
  • 2012
  • 2011
  • 2010
  • 2009
  • 2008
  • 2007
  • 2006
  • 2005
  • 2004
  • 2003

Recent Posts

  • Vacancy Announcement: Finance Officer

  • Durability of immunogenicity at 5 years after a single dose of human papillomavirus vaccine compared with two doses in Tanzanian girls aged 9-14 years: results of the long-term extension of the DoRIS randomised trial.

  • Hospitalization outcomes in people living with HIV on Dolutegravir-based regimen in Mwanza, Tanzania: a comparative cohort.

  • Vacancy Announcement: Laboratory Sample Archivist

  • HIV and CKD in the Tenofovir Era: A Prospective Parallel-Group Cohort Study From Tanzania.

Receive our latest news straight to your inbox

CONTACT US

Contact us through the address below
Mwanza Intervention Trials Unit.

MITU, Isamilo Street,
P.O. Box11936,
Mwanza, Tanzania.

info@mitu.or.tz

+255 28 2500019

WHO WE ARE

  • History & Background
  • Mission & Values
  • Strategic Plan
  • Organization Structure
  • Our Team

WHAT WE DO

  • Research Programme
  • Capacity Building
  • Research Facilities

OUR SOCIAL

  • Facebook
  • Twitter
  • LinkedIn
  • Instagram

OUR PARTNERS

Tweets by mituorg
© 2021 MITU | All rights reserved.
TOP